In a group of 500 healthy Dutch Caucasian blood donors, we determined the allelic frequency of the CYP3A5*2, *3, *4, *5, *6, and *7 alleles by use of newly developed PCR-restriction fragment length polymorphism assays. Results: The frequency of the defective CYP3A5*3 allele in the Dutch Caucasian population was 91%, followed by the CYP3A5*2 (1%) and CYP3A5*6 (0.1%) alleles. The CYP3A5*4, *5, and *7 alleles were not detected. Conclusions: On the basis of its allelic frequency, screening for the CYP3A5*3 allele in the Caucasian population is extremely relevant. In addition, screening for the CYP3A5*2 allele may be taken into consideration in individuals heterozygous for the CYP3A5*3 allele.
The CYP3A isoenzymes constitute the largest portion of cytochrome P450 protein in the liver and small intestine (1) (2) (3) . The four members of this subfamily, CYP3A4, CYP3A5, CYP3A7, and CYP3A43 (4, 5 ) , are located adjacent to each other on chromosome 7q21 and are responsible for the metabolism of 50 -60% of all currently prescribed drugs. In addition, two pseudogenes, CYP3AP1 and CYP3AP2, have been identified (6 ) . To date, CYP3A4 has been regarded as the most important enzyme of this subfamily because it forms the bulk of CYP3A protein and mRNA in the liver in most individuals (1) (2) (3) . Its catalytic activity may show up to 90-fold variation (7 ) . CYP3A7 is expressed mainly during fetal life where it accounts for ϳ50% of the total CYP protein (8 ) . After birth, expression is usually silenced. For the recently described CYP3A43, no protein expression data are currently available (9 ) . CYP3A5 protein was previously detected in the livers of some, but not all, adult Caucasian individuals (8, 10 -14 ) . The basis for this variation in expression was not known.
In a recent study, Kuehl et al. (15 ) demonstrated that only people with at least one CYP3A5*1 allele actually expressed CYP3A5 protein. Using DNA sequencing, they identified the CYP3A5*3 and *6 alleles. The single-nucleotide polymorphisms in these alleles produced alternative splicing and protein truncation and thus absence of CYP3A5 activity. In another study, the livers of 10% of Caucasian individuals expressed CYP3A5 to a high extent (high expressers), whereas the remaining individuals showed on average nine times less activity (low expressers) (7 ). The major determinant for this variation in expression was a single-nucleotide polymorphism at position 6986, which in the g.6986G allele (CYP3A5*3) led to alternative splicing of CYP3A5 transcripts and absence of CYP3A5 protein; the g.6986A allele (CYP3A5*1) correlated with high expression (7, 15 ) . Because CYP3A5 may represent up to 50% of the total hepatic CYP3A content in Molecular Diagnostics and Genetics people expressing CYP3A5, this gene may be the most important genetic contributor to interindividual and interracial differences in CYP3A-dependent drug clearance. Detection of CYP3A5 variant alleles, and knowledge about the allelic frequencies in the population, will be extremely useful in establishing the clinical relevance of CYP3A5 genotyping to optimize pharmacotherapy. To date, several variant alleles have been identified (CYP3A5*2 through *7) by sequencing (7, 10, 15, 16 ) . For screening purposes, we developed PCR-restriction fragment length polymorphism (PCR-RFLP) assays for the detection of CYP3A5 variant alleles. We report here the allelic frequencies of CYP3A5 variant alleles in a group of 500 healthy Dutch Caucasian volunteers.
Materials and Methods samples and dna isolation
After receiving informed consent, we obtained EDTAwhole blood from 500 healthy Dutch Caucasian volunteers. We isolated genomic DNA from 300 L of blood with the GenomicPrep Blood DNA Isolation Kit (Amersham Pharmacia Biotech) and estimated DNA yields by measuring the absorbance at 260 nm (A 260 ). The Medical Ethical Committee of the University Hospital Rotterdam approved the study.
pcr-rflp for cyp3a5 variant alleles
For a 50-L PCR, we used ϳ50 ng of genomic DNA. The PCR mixture contained 1ϫ buffer [10 mM Tris-HCl, pH 8.3, 1.5 mM MgCl 2 , 50 mM KCl, and 10 mg/L gelatin (Perkin-Elmer)], 0.2 mM each of the deoxynucleotide triphosphates (Roche), 1.25 U of AmpliTaq Gold (PerkinElmer), and 40 pmol each of the forward and reverse primers ( Table 1 ). The underlined nucleotides are mismatches with the CYP3A5 sequence, creating restriction sites in the PCR product. PCR conditions were as follows: 7 min at 94°C; 35 cycles of 1 min at 94°C, 1 min at 55°C, and 1 min at 72°C; and finally 7 min at 72°C. The PCR product was sequenced, confirming that indeed only the CYP3A5 gene was amplified. The PCR product (10 L) was then digested with the appropriate restriction enzyme (Roche; Table 1 ) in a total volume of 15 L for 2 h at 37°C and subsequently analyzed on a 4% agarose/Trisborate-EDTA gel with ethidium bromide staining. The fragments obtained for wild-type and variant alleles are indicated in Table 1 . We confirmed the presence of variant alleles of CYP3A5 by direct sequencing of the PCR product on an automated ABI 310 capillary sequencer (PerkinElmer), using the Big Dye Terminator Cycle Sequencing Kit (Perkin-Elmer).
Results
On the basis of the published CYP3A5 variant alleles, we developed specific PCR-RFLP tests for CYP3A5*2 through *7 and applied those in a large-scale genotyping study on samples obtained from 500 healthy Caucasian volunteers (Fig. 1) . The frequency of individuals that were wild type, heterozygous, or homozygous for the variant alleles is depicted in Table 2 . The CYP3A5*3 allele was abundantly present in our population, with an allelic frequency of 91.7%. Only one individual was homozygous wild type for CYP3A5*3. The CYP3A4*2 allele was found in 10 individuals, all heterozygotes, giving an allelic frequency of 1%. One individual was heterozygous for the CYP3A5*6 allele. The CYP3A5*4, *5, and *7 alleles were not detected in our study population. Among the 84 persons who were heterozygous or wild type for the CYP3A5*3 allele, only one was also heterozygous for another variant allele (CYP3A5*2). Because heterozygotes and wild types for CYP3A5*3 may have CYP3A5 activity, we estimate that 83% of Dutch Caucasians do not have CYP3A5 enzymatic activity.
Discussion
CYP3A enzymes are the predominant cytochrome P450 proteins in the human liver and play an important role in the metabolism of numerous exogenous and endogenous substrates. CYP3A5 is polymorphically expressed and may account for up to 50% of CYP3A content (15 ) . Recently, six variant alleles were described (7, 15 ) . Homozygosity for the allele g.6986G was strongly correlated with decreased CYP3A5 activity [factor of 2-3 (15 ) ], whereas the wild-type CYP3A5*1 allele (g.6986A), present in either homozygous or heterozygous form, correlated with high CYP3A5 activity. In addition, individuals with a CYP3A5*1 allele had threefold higher total CYP3A protein when compared with individuals homozygous for CYP3A5*3 (15 ) . Thus, CYP3A5 expression may be the most important factor determining the total CYP3A content of the human liver.
In a large-scale screening for CYP3A5 variant alleles among 500 healthy individuals, we conclude that the CYP3A5*3 allele is abundantly present in the Dutch Caucasian population, displaying an allelic frequency of 91%. This finding is in agreement with the reported frequency of 95% found in 183 samples from Caucasian patients from Germany and Switzerland (7 ). For comparison, the CYP3A5*3 allele was detected in 73% of Chinese, 71% of Japanese, 70% of Korean, and 27% of AfricanAmerican individuals (7 ). The CYP3A5*2 allele, encoding a g.27289C3A allele in exon 11, was found in 2% of the individuals (allelic frequency, 1%) and may thus be regarded as a genetic polymorphism in this population (17 ) .
A previous study involving 19 Caucasian individuals reported an allelic frequency of 5% (n ϭ 19) (10 ). This allele was not found when 45 African-American genomic DNA samples were investigated, suggesting that in this ethnic group the allelic frequency is Ͻ1% (7 ). Heterozygosity for the CYP3A5*2 allele, however, may potentially affect CYP3A5 expression in individuals who are already heterozygous for CYP3A5*3. We found only one individual heterozygous for both the CYP3A5*2 and *3 alleles, and this individual may thus lack CYP3A5 activity despite being heterozygous for the CYP3A5*3 allele. The allelic frequencies of the CYP3A5*4, *5, *6, and *7 alleles were Յ0.1%, and these variant alleles are therefore regarded as less relevant for screening purposes in the Caucasian population. In African Americans, the CYP3A5*6 allele (a g.14690G3A variant in exon 2, leading to the skipping of exon 7) has an allelic frequency of 13% (n ϭ 45) (7 ), suggesting a significant difference in the distribution of this allele between African Americans and Caucasians. This also holds for the CYP3A5*7 allele, which encodes a single nucleotide (T) insertion at g.27131 that leads to termination of the open reading frame; this allele was found in 9 of 45 African Americans, giving an allelic frequency of 10% (7 ) . Apparently, the CYP3A5*6 and/or the CYP3A5*7 alleles do not cosegregate with the CYP3A5*3 allele in Caucasians, as was suggested for African Americans (7 ) . On the basis of the CYP3A5 variant alleles detected in our group of 500 Dutch Caucasians, we deduce that 83% may have low expression of CYP3A5. This is in agreement with the finding that 10% of Caucasians were high expressers of CYP3A5 (7 ) .
In conclusion, we showed that screening for the CYP3A5*3 alleles is relevant in the Caucasian population. Genotyping for the CYP3A5*2 allele in CYP3A5*3 heterozygotes may subsequently be performed. In addition, we presented simple DNA-based tests that can be used to investigate interindividual differences in CYP3A5 expression. This will greatly facilitate studies on the relevance of pharmacogenetics for CYP3A genes with respect to disease risk and to the pharmacokinetics and pharmacodynamics of many drugs. 
